Evidence map›Paper›PMID 25217524›Full record

ArticleCancer research2014

The Notch pathway inhibits TGFβ signaling in breast cancer through HEYL-mediated crosstalk.

Liangfeng Han, Adam Diehl, Nguyen K Nguyen, Preethi Korangath, Weiwen Teo, Soonweng Cho, Scott Kominsky, David L Huso, Lionel Feigenbaum, Alan Rein and 4 more

Abstract read
In one paragraph

Article in Cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. HEYL-mediated activation of LAMA3 influences radiotherapy response in esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Mammary Development and Breast Cancer: a Notch Perspective.Journal of mammary gland biology and neoplasia · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Liangfeng HanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Adam DiehlDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nguyen K NguyenDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Preethi KorangathDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Weiwen TeoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Soonweng ChoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Scott KominskyDepartment of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
David L HusoDepartment of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Lionel FeigenbaumLaboratory Animal Science Program, Science Applications International Corporation, Frederick, Maryland.
Alan ReinHIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland.
Pedram ArganiDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Goran LandbergBreakthrough Breast Cancer Unit, School of Cancer, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom.
Manfred GesslerDevelopmental Biochemistry, Comprehensive Cancer Center Mainfraken and Theodor-Boveri-Institute, Biocenter, University of Wuerzburg, Wuerzburg, Germany.
Saraswati SukumarDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. saras@jhmi.edu.
Johns Hopkins University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
Intramural NIH HHSNCI NIH HHS P30 CA006973NIGMS NIH HHS T32 GM008752
6 · The paper itself

Abstract

Acquired resistance to TGFβ is a key step in the early stages of tumorigenesis. Mutations in TGFβ signaling components are rare, and little is known about the development of resistance in breast cancer. On the other hand, an activated Notch pathway is known to play a substantial role in promoting breast cancer development. Here, we present evidence of crosstalk between these two pathways through HEYL. HEYL, a basic helix-loop-helix transcription factor and a direct target of Notch signaling, is specifically overexpressed in breast cancer. HEYL represses TGFβ activity by binding to TGFβ-activated Smads. HeyL(-/-) mice have defective mammary gland development with fewer terminal end buds. On the other hand, HeyL transgenic mice show accelerated mammary gland epithelial proliferation and 24% of multiparous mice develop mammary gland cancer. Therefore, repression of TGFβ signaling by Notch acting through HEYL may promote initiation of breast cancer.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsBreast NeoplasmsCells, CulturedFemaleHumansMiceMice, TransgenicReceptors, NotchRepressor ProteinsSignal TransductionSmad3 ProteinTransforming Growth Factor betaBasic Helix-Loop-Helix ProteinsHEYL protein, humanReceptors, NotchRepressor ProteinsSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor beta

Identifiers

PMID25217524
PMCPMC4233182
OpenAlexW2066855407

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.